Global Nuclear Imaging Market 2015 - 2019: Cardiarc, Digirad, Gamme Medica, GE healthcare & Hologic Dominate the $15.51 Billion Industry
Major factors for the growth of the market are increasing use of SPECT and PET analysis in radiopharmaceuticals, increased awareness of people for radiopharmaceuticals, and ready availability of radiopharmaceuticals.
Novel applications such as Alzheimer's and continually expanding oncology application segment also drive the market. Till now, SPECT imaging was the mainstream modality for nuclear medicine applications like nuclear cardiology procedures. However, the trend is soon going to flip upside down because of global shortage of molybdenum-99 isotope which is in turn will lead to shortage of Technetium-99, which is the daughter product of molybdenum. Hence, PET imaging products which includes hybrid PET-CT scanners holds a potential market size in coming years.
The cost associated with PET-CT service contract is usually 105 of the system purchase price annually and can be as high as $275,000 per year. The emerging market trend is fusion of nuclear imaging with different diagnostic imaging products such as PET/CT, SPECT/CT, and MRI/PET. This provides full gamut of imaging scans through the same unit and at the same time. PET market is expected to witness more growth compared to SPECT imaging as it provides higher resolution images and the lack of availability of technetium-99m is propelling industry to look for alternative diagnostic procedures.
Major players in the market are Cardiarc Ltd., Digirad Corporation, Gamme Medica Inc., GE healthcare, Hologic Inc. etc. Mergers and acquisitions of small and medium sized manufacturers to enter in overseas market is another strategy adopted by multinational players.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Market Overview
4. Porters Five Force Analysis
5. Market Segmentation
6. Competitive Landscape
7. Company Profiles
For more information visit http://www.researchandmarkets.com/research/6n89sg/global_nuclear
Media Contact:
Laura Wood, +353-1-481-1716, [email protected]
